UG

UNITED GUARDIAN INC - 10-Q Summary

Business Context and Reporting Period

This is a Quarterly Report (Form 10-Q) for UNITED GUARDIAN INC for the period ended March 31, 2010. The company is a Delaware corporation engaged in the research, development, manufacturing, and marketing of cosmetic ingredients, personal care products, pharmaceuticals, and specialty industrial products. Its primary facility is located in Hauppauge, New York. The company is classified as a smaller reporting company.

Key Financial Metrics

Debt and Liquidity: The company reported no long-term debt payments in the quarter. Total current liabilities decreased significantly to $1,866,721 from $2,920,674 at year-end 2009, primarily due to the payment of dividends payable. The company maintains a strong liquidity position with total current assets of $17,678,398.

Material Changes vs. Prior Period

• Revenue Decline: Net sales decreased by 8.2% ($318,228) compared to Q1 2009. This was driven by a 32.2% drop in medical (non-pharmaceutical) product sales due to a specific customer resuming purchases later in the quarter, and an 11.4% drop in sales to the largest personal care distributor due to order timing.
• Pharmaceutical Growth: Pharmaceutical sales increased by 17.7% ($116,259), attributed to customers purchasing larger volumes in advance of a price increase implemented on April 1, 2010.
• Expense Reduction: Operating expenses decreased by 12.9% ($91,936), primarily due to lower payroll and professional fees.
• Cash Flow: Net cash provided by operating activities decreased by 46% to $953,986, largely due to increases in inventory and accounts receivable balances.
• Investing Activities: The company used $2,175,725 in cash for investing activities, primarily for the purchase of marketable securities ($2.96M), offset by proceeds from sales ($600k).
• Dividends: The company paid dividends of $1,582,860 ($0.32 per share), an increase from $1,385,003 ($0.28 per share) in the prior year period.

Outlook, Risks, and Management Commentary

Management Commentary: Management attributes the sales decline in personal care products to the timing of orders from its largest distributor and expects this to normalize. The pharmaceutical sales increase is viewed as a result of forward-buying ahead of a price hike. The company believes its working capital is sufficient to support operations for the next twelve months and does not anticipate significant capital expenditures for the remainder of 2010.

Pension Plan: The company received regulatory approval in March 2010 to terminate its defined benefit pension plan, with termination expected by the end of 2010. Upon termination, non-vested benefits will become fully vested.

Risks and Contingencies:

• Concentration Risk: The company relies heavily on a few distributors, particularly International Specialty Products Inc. (ISP), for personal care products.
• Customer Concentration: A significant portion of medical product sales comes from a single customer, whose purchasing patterns can cause volatility.
• Market Conditions: Risks include general economic conditions, competition, and the ability to develop new products.

Unusual Items: The filing notes a realized loss of $5,564 on the sale of investments. There were no legal proceedings or defaults on senior securities reported.

Investor Verification Checklist

• Customer Concentration: Verify the stability of the largest personal care distributor (ISP) and the single major medical product customer.
• Pharmaceutical Pricing: Confirm the impact of the April 1, 2010 price increase on future revenue sustainability versus one-time forward-buying.
• Inventory Levels: Review the increase in inventory ($348,906 cash outflow) to ensure it aligns with demand forecasts and is not becoming obsolete.
• Pension Termination: Monitor the timeline and financial impact of the defined benefit plan termination expected by year-end 2010.
• Dividend Policy: Assess the sustainability of the increased dividend payout ($0.32/share) given the decline in operating cash flow.